What helps. What’s uncertain.
What the studies actually say.
A practical guide for adult men exploring lifestyle, supplements, peptides and testosterone replacement. Clear tradeoffs, original research and a little less noise.
Research checked • Includes Thailand price examples
Fatigue, low libido and changes in performance have many possible causes. A symptom checklist cannot diagnose low testosterone.
Diagnosis requires compatible symptoms and consistently low testosterone on separate early-morning blood tests. Clinicians assess the cause, repeat morning fasting total testosterone and use free-testosterone testing when appropriate. Routine screening of asymptomatic men is not recommended.
Guideline ↗All exogenous testosterone routes can suppress sperm production, sometimes to zero. Recovery can take months, occasionally years, and is not guaranteed to be complete. Discuss future parenthood before treatment; a different route or adding another hormone is not a guaranteed workaround.
Guideline ↗Total, free and salivary testosterone are not interchangeable. A laboratory increase, a symptom improvement and a pregnancy or live birth are separate outcomes. Results in selected men with low testosterone do not establish enhancement benefits in healthy men with normal levels.
Guideline ↗Study ↗Clinical guidance recommends against starting testosterone when planning fertility soon, or with breast/prostate cancer, unresolved concerning prostate findings, raised hematocrit, untreated severe sleep apnea, severe urinary symptoms, uncontrolled heart failure, heart attack or stroke within the preceding six months, or thrombophilia. A clinician must assess these issues and current product guidance. This list cannot clear you for treatment.
Guideline ↗Addressing a reversible cause is different from pushing a normal level higher. Explore the study populations, comparisons and limits behind each claim.
How to read these cards: labels are informal editorial assessments, not formal GRADE ratings. These studies are not head-to-head comparisons; their effect sizes cannot be ranked on a single “boost” scale.
Review ↗11 approaches · open a card for study detail
The clearest natural-intervention case is reversing obesity-related suppression.
24-study meta-analysis · overweight/obese men · varied durations
Diet-related weight loss was associated with an average total-testosterone rise of 2.87 nmol/L (about 83 ng/dL); 95% CI 1.68–4.07 nmol/L. This was an average before/after change across heterogeneous studies, not a placebo-adjusted treatment effect. The review also included surgery; this number is the dietary estimate.
A separate review of seven randomized trials found calorie restriction raised testosterone in three of four studies in overweight/obese men, but lowered it in two of three in normal-weight men.
These results do not extend to already-lean men. Prolonged under-fuelling can have the opposite effect.
Meta-analysis ↗Review ↗Avoiding sleep loss is sensible; a guaranteed “sleep boost” is not established.
10 healthy young men · about one week of sleep restriction
After restricting time in bed to five hours nightly, mean waking-hours testosterone fell from 18.4 to 16.5 nmol/L (about 531 to 476 ng/dL), compared with the rested condition.
This very small experiment measured daytime levels. It did not test whether extending already-adequate sleep produces a lasting rise or treats clinical testosterone deficiency.
Sleep symptoms and possible sleep apnea deserve assessment on their own merits.
Study ↗Fitness benefits do not require a rise in resting testosterone.
11 randomized trials · 421 insufficiently active men, ages 19–75 · median 12 weeks
Exercise training had essentially no average effect on resting testosterone compared with control: standardized mean difference 0.00 (95% CI −0.20 to 0.20).
Fitness and body composition can improve without a higher resting hormone result. A brief post-workout spike is a different outcome.
This finding is about resting testosterone, not whether exercise is worthwhile.
Meta-analysis ↗Small trials show hormonal signals; everyday symptom benefit remains uncertain.
Training trial: 57 enrolled, 50 completed · eight weeks · placebo-controlled
In novice male lifters aged 18–50, both groups trained. Total testosterone rose 96.2 ng/dL versus 18.0 ng/dL with placebo, about 78 ng/dL greater change. Testosterone was a secondary outcome and was normal at baseline. Greater strength gains do not prove the hormone change caused them.
In a separate crossover trial of 57 overweight men aged 40–70 with mild fatigue, eight weeks of a different extract produced a 14.7% greater increase in salivary testosterone than placebo. There was no significant benefit for fatigue, vigor or sexual well-being; 50 completed the first period and 43 completed 16 weeks.
Extracts differ. Rare liver injury, thyroid/autoimmune concerns, medication interactions and uncertain long-term safety matter.
Study ↗Study ↗Safety ↗A modest signal in some low-testosterone groups; healthy-men benefit is unproven.
105 men, ages 50–70, total T below 300 ng/dL · 12 weeks · placebo-controlled
In one active arm, total testosterone rose 200.5 → 225.0 ng/dL; placebo changed 183.0 → 177.9. The roughly 30 ng/dL difference in change is arithmetic from group means, not an adjusted estimate with its own confidence interval. Free testosterone did not differ significantly between groups. Fatigue/quality-of-life improvements were reported.
The proprietary-extract trial was manufacturer-funded; two authors were manufacturer employees. A five-trial meta-analysis included 232 unique participants, with high heterogeneity (I² 87%) and publication-bias concerns. The healthy-men subgroup result was not statistically significant.
EFSA could not establish safety for one assessed extract because of preclinical DNA-damage concerns. This is not proof of cancer in humans.
Study ↗Meta-analysis ↗Safety ↗Positive early findings are not consistently reproduced against placebo.
Trials: 120 men for 12 weeks (2016); 95 completers for 12 weeks (2024)
A 2016 trial in men aged 43–70 reported better testosterone, symptom and sexual-function measures with a proprietary extract than placebo.
In the newer industry-funded trial, men aged 40–80 taking active preparations had a 9% plasma-total-testosterone advantage over placebo that was not statistically significant (p=.122). Salivary testosterone rose significantly, but subjective outcomes did not improve. The preparation also included nutrients.
Within-group improvement is not proof of superiority to placebo. Results cannot be assigned to every fenugreek product.
Study ↗Study ↗Correcting a deficiency is different from taking extra zinc when intake is adequate.
Nine marginally zinc-deficient older men · six months · no randomized placebo comparison
Testosterone rose from 8.3 to 16.0 nmol/L (about 239 to 461 ng/dL) during zinc replacement. The same report included an induced-deficiency experiment in only four young men.
The replacement study was very small and lacked a randomized placebo comparison. It does not establish an enhancement benefit in zinc-replete men.
These are deficiency findings, not evidence for a universal testosterone booster.
Study ↗A deficiency may need treatment for other reasons; a testosterone gain is unreliable.
100 men enrolled, 94 completed · 12 weeks · randomized placebo-controlled trial
Men screened with low testosterone and vitamin D below 75 nmol/L had no significant total-testosterone benefit: estimated effect −0.188 nmol/L (95% CI −1.50 to 1.12).
The wider literature is mixed. This is not a claim that no vitamin D trial has ever been positive.
Do not treat a nutrient result or a supplement label as a diagnosis of hormone deficiency.
Study ↗The common testosterone claim lacks convincing support.
21 healthy young men · four weeks · randomized controlled study
The study found no testosterone increase with Tribulus compared with control. A small, short negative study cannot settle every possible use, but it does not support marketed testosterone-enhancement claims.
Sexual symptoms and serum testosterone are different outcomes; improvement in one cannot be assumed from the other.
Study ↗Results in trained men do not support a dependable boost.
24 resistance-trained men · 14 days · randomized study
The lower studied quantity showed no benefit; the higher quantity lowered total and free testosterone. A separate 28-day trial found no advantage for hormones, strength or body composition.
Small, short studies do not justify a self-directed regimen or a reliable long-term benefit claim.
Study ↗Study ↗There is no robust case for using boron to raise testosterone.
19 male bodybuilders · seven weeks · placebo-controlled study
The study found no advantage in testosterone, strength or lean mass versus placebo. The broader literature is small and inconsistent.
An isolated biomarker finding is not enough to establish meaningful clinical benefit.
Study ↗No matching approaches. Try a different word or choose “All approaches.”
Excessive or chronic alcohol use can suppress testosterone. Studies are heterogeneous; there is no dependable randomized “boost” estimate here for cutting down.
Review ↗Extract identity, purity and interactions matter. FDA has documented hidden steroid-like substances in some bodybuilding products. This is a category-level warning, not an accusation about every supplement or seller.
Safety ↗Plants can provide starting materials for laboratory-manufactured, body-identical hormones. Eating the plant is not equivalent to taking the manufactured hormone. Wild yam is not established as a testosterone treatment.
Background ↗Background ↗A specialist prescription hormone, an experimental infusion and a retail “research peptide” are not interchangeable categories.
A prescription hormone with legitimate specialist uses.
Human chorionic gonadotropin acts like LH to stimulate testicular testosterone production. Selected cases of hypogonadotropic hypogonadism and fertility care may use it; fertility treatment may also require FSH. It is not a general wellness supplement.
A randomized placebo-controlled study of 40 men over 60, lasting three months, found testosterone and estradiol rose about 150% and lean mass increased about 2 kg. Strength and physical function did not improve. This establishes biological activity, not anti-aging benefit or long-term safety.
Breast tenderness/gynecomastia and fluid retention are potential harms. Sperm-count changes do not establish pregnancy or live-birth benefit.
A laboratory signal is not a retail treatment protocol.
In an infusion experiment involving just four healthy men, testosterone rose from 16.6 to 24.0 nmol/L over 22.5 hours. That does not establish durable symptom benefit, long-term safety or fertility success for commercial kisspeptin regimens.
Pulsatile GnRH has a specialist role in selected GnRH-deficiency disorders. It is not routine treatment for nonspecific symptoms.
Study ↗Guideline ↗SERMs belong in a separate conversation.
Trials in selected men with secondary hypogonadism found enclomiphene increased testosterone while preserving sperm counts compared with testosterone gel. That does not establish pregnancy benefit, equivalent symptom relief or long-term safety.
Clomiphene use for male hypogonadism is off-label in the US. EMA refused authorization for enclomiphene over insufficient clinical-benefit evidence and blood-clot concerns. This does not determine Thai authorization.
Study ↗Patient guide ↗Regulator ↗Not established testosterone-deficiency treatments.
FDA identifies limited safety information, peptide-quality and immunogenicity concerns, and reported adverse events. An event during exposure does not by itself prove causation.
Compounding-list status is not drug approval. Current FDA material places BPC-157 and CJC-1295 in a withdrawn-nomination table; ipamorelin also appears under 503B category 2. These administrative categories do not establish benefit or safety.
Safety ↗For clinically confirmed, symptomatic deficiency, gel and injections can restore testosterone. The right choice depends on cause, risks, fertility plans, cost and treatment burden.
Route changes the tradeoffs, not the need for medical care. All exogenous routes can suppress fertility. Follow-up assesses symptoms, testosterone, hematocrit, blood pressure and individualized prostate risk. Guideline ↗Guideline ↗
A needle-free, adjustable option with relatively steady exposure. Absorption varies.
Still systemic testosterone: sperm suppression, blood-count and blood-pressure monitoring remain relevant. It can transfer to others, especially children and pregnant partners. Follow the exact product’s handwashing, covering and skin-contact instructions.
Product label ↗Effective replacement, often with a lower medicine cost.
Requires injections; peaks and troughs may affect symptoms. Hematocrit elevation requires attention. Unit prices do not establish total treatment cost.
Guideline ↗An alternative injection route where appropriate for the exact product.
Blood-pressure, hematocrit and injection-site effects remain relevant. Products and local authorizations differ; this is not a universal substitution for intramuscular use.
Study ↗Relatively stable exposure and fewer administration visits.
Slower to adjust or stop; clinician administration and product-specific pulmonary oil microembolism/anaphylaxis precautions matter. The cited Aveed label is US-specific.
Product label ↗A needle-free route capable of restoring testosterone in selected patients.
Food and absorption requirements differ by formulation. Blood pressure needs monitoring. Evidence for newer US Jatenzo does not automatically apply to older oral products or establish Thai availability.
Study ↗Needle-free, without the gel skin-transfer issue.
Skin irritation can limit use. Local availability may be limited; current Thai supply was not verified.
Guideline ↗Short-acting, needle-free formulation.
Nasal irritation and some nasal conditions can limit use. It is not a guaranteed fertility-preserving option. Current Thai supply was not verified.
Guideline ↗Absorption through gum tissue avoids injections.
Gum irritation and repeated applications are burdens. Current Thai supply was not verified.
Guideline ↗Long intervals between insertion procedures.
Insertion, extrusion, bleeding and infection risks; harder to adjust or stop rapidly. Current Thai supply was not verified.
Guideline ↗Open-label randomized study: 166 men on Jatenzo and 56 on Axiron, about 3–4 months. About 87% in each group reached the study’s normal average-testosterone range. Oral TU increased average systolic BP by about 3–5 mmHg. This is formulation-specific evidence.
Study ↗Single-arm study: 150 men; 92.7% reached the study target at week 12. This is a normalization rate, not “92.7% felt better.” Hematocrit, hypertension and PSA findings mattered. No comparator means no superiority claim.
Study ↗Network meta-analysis: 29 randomized trials, 3,393 men. All included formulations raised mean hematocrit. Only IM cypionate/enanthate versus patch differed significantly between formulations; no precise overall safety ranking follows.
Meta-analysis ↗The strongest trials studied selected men with low testosterone. Their results do not establish enhancement benefits in healthy people with normal levels.
The Testosterone Trials enrolled 790 symptomatic men aged 65+ with low testosterone. A year of gel versus placebo produced moderate sexual-function benefit and some mood benefit, but no primary vitality benefit.
Study ↗TRAVERSE: 5,246 men aged 45–80 with symptoms, two low tests and existing/high cardiovascular risk. Over mean 33-month follow-up (about 22 months’ treatment), major cardiovascular events occurred in 7.0% with gel versus 7.3% with placebo; HR 0.96, 95% CI 0.78–1.17.
This supports noninferiority under the trial conditions, not zero risk or cardiovascular prevention. Atrial fibrillation, acute kidney injury and pulmonary embolism were more frequent with testosterone.
Study ↗In the TRAVERSE fracture subtrial, clinical fractures occurred in 3.50% with testosterone versus 2.46% with placebo over median 3.19 years; HR 1.43, 95% CI 1.04–1.97. This does not support promising fracture prevention.
Neither trial establishes lifetime safety, safety of high-dose enhancement or equal safety across every route.
Study ↗Study ↗In February 2025, FDA announced removal of boxed-warning language about increased major cardiovascular outcomes and required additional blood-pressure information/warnings. Its current page also reports a June 2026 request to remove the age-related limitation of use and revise prostate-cancer/BPH safety language.
These are requested US labeling updates, not proof that every product label has changed, that prostate cancer is no concern, or that Thailand adopted them. The Endocrine Society’s July 2026 statement still emphasizes accurate diagnosis, monitoring and unresolved long-term safety.
US regulator ↗US regulator ↗Statement ↗Published examples in Thai baht (THB), checked 8 October 2026. Commercial price sources are not endorsements, live quotes or verified stock.
per pack of 30 × 50 mg sachets
Consultations and labs are not stated as included. Pack duration depends on the prescribed amount. Stock was not verified.
Commercial price source ↗per listed 250 mg injection/service item
Medicine, administration, consultation and lab fees are not clearly separated. Brand and pack volume are not specified.
Commercial price source ↗per 1,000 mg / 4 mL vial
Explicitly excludes tests, consultation, injection service, follow-up and other medical service fees.
Commercial price source ↗40 mg capsules listed in the Thai dataset
No current legitimate retail quote or stock was verified. An older government reference price would not be a current retail price.
Thai registry ↗H.U.M. publishes total testosterone at ฿800 per test, a free-testosterone panel at ฿3,290, and a ฿800 / 30-minute consultation. These are separate listed items, not a verified complete work-up. Two total-testosterone tests would be ฿1,600 by arithmetic, before other fees.
Commercial price source ↗No provider package explicitly guaranteeing two separate morning testosterone measurements was verified here. Which additional tests are appropriate depends on clinical assessment. A broad commercial panel is not a universal requirement.
Guideline ↗The accessible Thai FDA records label their dataset 30 June 2025. Listings include ANDROGEL 50 MG (1C 90/54(N)), TESTOVIRON DEPOT (1C 107/50), NEBIDO (1C 84/50(N)), HOM TESTOCAPS (1A 128/60) and TESTOS (1A 129/60).
These are documented listings, not independently revalidated active October 2026 approvals, authentic-product guarantees or current stock checks. Testogel, Andriol and Sustanon were not independently verified for current Thai registration and legitimate supply in this review; that is an evidence limitation, not a claim that they are unavailable or prohibited.
Thai registry ↗Thai registry ↗Thai registry ↗Thai registry ↗Four clinician-led videos selected for educational fit and reach. A curated shortlist, not a ranking of all YouTube or a complete medical audit.
Popularity is not evidence quality. Views and rounded likes are from YouTube search-index snapshots retrieved 8 October 2026, not live counts. Likes/views are approximate engagement measures; public dislike totals are not reliable, so no like/dislike ratio is shown.
Videos open on YouTube. There are no embedded players, autoplay or third-party thumbnails here.
Rena Malik, M.D.
An accessible overview of weight management, movement, diet, sleep and stress, from a urologist.
Older educational overview. A temporary post-workout testosterone rise is not proof of a lasting increase or extra muscle growth. Diet, sleep and supplement claims need the study-by-study qualifications on this site; benefits are not guaranteed and lifestyle cannot reverse every cause of hypogonadism.
Board-certified urologist and pelvic surgeon.
Reviewed the creator's companion description and study list, plus indexed transcript passages. Full original video playback/transcript could not be retrieved. Do not describe this as a complete video audit.
Creator promotes appointments, memberships, a book and affiliate product links.
Creator's original video page ↗
Creator's podcast replay with cited papers ↗
Doctor Mike
Start at 08:47 for the testosterone discussion. Useful questioning of supplement marketing, symptoms, repeat testing and inappropriate performance-enhancement use.
A long conversation, not a systematic review. Clinical anecdotes and speculative explanations appear alongside evidence; neither proves a supplement works or fails. The discussion predates 2025–2026 labeling changes, so use this site's current safety notes.
Physician host interviewing board-certified urologist Rena Malik.
Read the publicly accessible transcript's testosterone/supplement discussion, including approximately 09:50–27:00 in the podcast transcript. Podcast ad insertion shifts those transcript timestamps relative to YouTube; 08:47 comes from the official YouTube chapters. The transcript is a third-party transcription of the speakers, not independent medical evidence.
YouTube description promotes a media course and Patreon. Use the medical discussion independently of products or memberships.
Official YouTube video and chapter list ↗
Public transcript of the interview ↗
Rena Malik, M.D.
A specialist-led introduction to who may benefit from TRT, what it can do and the need for individualized care and monitoring.
Recorded in 2021, before TRAVERSE and later regulatory changes. Read current evidence alongside it, especially fertility suppression, hematocrit and blood-pressure monitoring. It is not a dosing guide or proof that one delivery method is best.
Board-certified urologists Rena Malik and Jonathan Clavell.
Reviewed the official description and creator's written companion. Original full transcript/playback was not accessible, so this is a provisionally selected educational companion rather than a fully audited recommendation.
Creator promotes appointments, memberships, a book and affiliate links.
Dr Brad Stanfield
A critical review of BPC-157's research history and the difference between a compounding advisory recommendation and drug approval.
BPC-157 is not an established testosterone-raising treatment. This video supports research literacy, not a peptide protocol. Regulatory discussion is dated July 2026; verify subsequent decisions separately. Mechanistic and safety uncertainties are not evidence of benefit.
General practitioner in Auckland, New Zealand; not an endocrinology specialist.
Read the creator's detailed companion write-up and its cited FDA committee materials/research links; original video playback was not retrieved.
Description promotes personalized health plans and Patreon. The host's wider business has included supplement marketing; credentials and popularity alone do not settle a claim.
Official YouTube video ↗
Creator's full companion write-up and references ↗
Original studies where available; reviews, professional guidance, official safety information and clearly labeled commercial price sources. Research is a snapshot, not an exhaustive systematic review.
Editorial method. Prioritize clinical outcomes over isolated hormone changes; show populations, comparators and limitations alongside numbers. Informal evidence labels are not formal GRADE assessments. No head-to-head ranking is inferred across unlike studies. A study of one extract or formulation does not validate every product with the same ingredient name.
Scope. General education for adult men concerned about testosterone. Not diagnosis, a prescribing or dosing guide, personal medical advice, or guidance for children, pregnancy or gender-affirming treatment. This guide does not claim clinician certification. Professional care and current local product guidance remain essential.
Privacy. This static guide has no analytics, cookies, account, forms or third-party embeds. Links to outside sites open only when selected; those sites have their own privacy practices. The hosting provider may maintain standard service logs.